Exchange: NASDAQ·Updated 07:57 PM EDT
ALT logo

ALTAltimmune Inc

$2.70
$0.06
(2.27%)
Today
Closed $2.70
$0.01
(0.37%)
After Hours
EarningsAug 11
Mkt Cap$525.08M
Vol11.69M
News
all
press releases
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Zacks
News Placeholder
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
Zacks
News Placeholder
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Zacks
News Placeholder
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Stocktwits
News Placeholder
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
Zacks
News Placeholder
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Zacks
News Placeholder
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.
Zacks
News Placeholder
Altimmune (ALT) Projected to Post Earnings on Tuesday
Altimmune (NASDAQ:ALT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-altimmune-inc-stock...
MarketBeat
News Placeholder
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead
VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.